Zvavahera Mike Chirenje1, Holly M Gundacker, Barbra Richardson, Lorna Rabe, Zakir Gaffoor, Gonasagrie Lulu Nair, Brenda Gati Mirembe, Jeanna M Piper, Sharon Hillier, Jeanne Marrazzo. 1. From the *University of Zimbabwe-University of California San Francisco Research Program, Harare, Zimbabwe; †SCHARP at Fred Hutchinson Cancer Research Center; ‡Department of Biostatistics, University of Washington, Seattle, WA; §Magee-Women's Research Institute, Pittsburgh, PA; ¶Medical Research Council, HIV Prevention Research Unit, Durban, South Africa; ∥CAPRISA-University of KwaZulu Natal, Durban, South Africa; **MU-JHU Research Collaboration, Kampala, Uganda; ††Division of AIDS/NIAID/US National Institutes of Health, Bethesda, MD; ‡‡University of Pittsburgh, Pittsburgh, PA; and §§University of Alabama at Birmingham, AL.
Abstract
BACKGROUND: In sub-Saharan Africa, there are limited data on the incidence of sexually transmitted infections (STIs) among women, largely because routine screening for asymptomatic infection is not performed. We conducted a secondary analysis to measure STI incidence rates and determine risk factors for new STI acquisition among women enrolled in the VOICE trial. METHODS: We analyzed data from 4843 women screened for chlamydia, gonorrhoea, syphilis, and trichomonas infection at baseline, annually, at interim visits when clinically indicated and at their study termination visit. Risk reduction counseling and condoms were provided throughout the trial. RESULTS: Twenty percent of evaluable participants had one or more curable STIs at baseline. Over 5660 person-years at risk (PYAR) of observation, incidence rates were 13.8% (95% confidence interval [CI], 12.7-14.8) PYAR for chlamydia, 3.5% (95% CI, 3.0-4.1) PYAR gonorrhea, 0.1% (95% CI, 0.6-1.1) PYAR syphilis, and 6.6% (95% CI, 5.8-7.2) PYAR trichomoniasis. South African sites had the highest incidence of chlamydia. The Uganda site had the highest incidence of gonorrhoea and syphilis, and Zimbabwe the lowest incidence overall. The majority of these cases were diagnosed at a routine scheduled testing visit. In multivariate analysis, positive baseline STI, younger than 25 years, being unmarried, and some alcohol consumption were associated with acquiring a new STI. CONCLUSIONS: We observed high rates of STIs during follow up among women in the VOICE study. Women living in human immunodeficiency virus endemic countries should be screened for common STIs.
RCT Entities:
BACKGROUND: In sub-Saharan Africa, there are limited data on the incidence of sexually transmitted infections (STIs) among women, largely because routine screening for asymptomatic infection is not performed. We conducted a secondary analysis to measure STI incidence rates and determine risk factors for new STI acquisition among women enrolled in the VOICE trial. METHODS: We analyzed data from 4843 women screened for chlamydia, gonorrhoea, syphilis, and trichomonasinfection at baseline, annually, at interim visits when clinically indicated and at their study termination visit. Risk reduction counseling and condoms were provided throughout the trial. RESULTS: Twenty percent of evaluable participants had one or more curable STIs at baseline. Over 5660 person-years at risk (PYAR) of observation, incidence rates were 13.8% (95% confidence interval [CI], 12.7-14.8) PYAR for chlamydia, 3.5% (95% CI, 3.0-4.1) PYAR gonorrhea, 0.1% (95% CI, 0.6-1.1) PYAR syphilis, and 6.6% (95% CI, 5.8-7.2) PYAR trichomoniasis. South African sites had the highest incidence of chlamydia. The Uganda site had the highest incidence of gonorrhoea and syphilis, and Zimbabwe the lowest incidence overall. The majority of these cases were diagnosed at a routine scheduled testing visit. In multivariate analysis, positive baseline STI, younger than 25 years, being unmarried, and some alcohol consumption were associated with acquiring a new STI. CONCLUSIONS: We observed high rates of STIs during follow up among women in the VOICE study. Women living in human immunodeficiency virus endemic countries should be screened for common STIs.
Authors: Louise M Causer; Belinda Hengel; Lisa Natoli; Annie Tangey; Steven G Badman; Sepehr N Tabrizi; David Whiley; James Ward; John M Kaldor; Rebecca J Guy Journal: Sex Health Date: 2015-03 Impact factor: 2.706
Authors: Sami L Gottlieb; Carolyn D Deal; Birgitte Giersing; Helen Rees; Gail Bolan; Christine Johnston; Peter Timms; Scott D Gray-Owen; Ann E Jerse; Caroline E Cameron; Vasee S Moorthy; James Kiarie; Nathalie Broutet Journal: Vaccine Date: 2016-04-19 Impact factor: 3.641
Authors: Lisa Natoli; Rebecca J Guy; Mark Shephard; Louise Causer; Steven G Badman; Belinda Hengel; Annie Tangey; James Ward; Tony Coburn; David Anderson; John Kaldor; Lisa Maher Journal: PLoS One Date: 2015-12-29 Impact factor: 3.240
Authors: Z Mike Chirenje; Nicholas Dhibi; H Hunter Handsfield; Elizabeth Gonese; Beth Tippett Barr; Lovemore Gwanzura; Ahmed S Latif; Dumisili Venessa Maseko; Ranmini S Kularatne; Mufuta Tshimanga; Peter H Kilmarx; Anna Machiha; Owen Mugurungi; Cornelis A Rietmeijer Journal: Sex Transm Dis Date: 2018-06 Impact factor: 2.830
Authors: Jodie Dionne-Odom; Andrew O Westfall; Barbara Van Der Pol; Karen Fry; Jeanne Marrazzo Journal: Sex Transm Dis Date: 2018-11 Impact factor: 2.830
Authors: Pooja Chitneni; Mwebesa Bosco Bwana; Moran Owembabazi; Kasey O'Neil; Paul Kato Kalyebara; Winnie Muyindike; Nicholas Musinguzi; David R Bangsberg; Jeanne M Marrazzo; Jessica E Haberer; Angela Kaida; Lynn T Matthews Journal: Sex Transm Dis Date: 2020-08 Impact factor: 3.868